Abstract
Although currently circulating H5N1 viruses are not efficiently transmitted from person to person, H5N1 influenza remains a major global threat. New treatment strategies are urgently needed. Now, researchers (one of whom is named on a patent relating to the generation and use of human monoclonal antibodies) have generated anti-H5N1 monoclonal antibodies (mAbs) from B-cells of four Vietnamese patients who survived H5N1 infections. They selected …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
